Navigation Links
Experimental antibody shows early promise for treatment of childhood tumor
Date:5/8/2014

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more than two-and-a-half years and without additional treatment.

Findings from the Phase I study were published recently online and will appear in the May 10 edition of the Journal of Clinical Oncology. The results prompted St. Jude to expand clinical trials of the monoclonal antibody hu14.18K322A to include patients newly diagnosed with neuroblastoma. Monoclonal antibodies are engineered in the laboratory to recognize and attach to specific markers carried on the cell surface.

Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common cancer diagnosed in the first year of life and accounts for 7 to 10 percent of childhood cancers. While certain patients, particularly infants, enjoy cure rates of 90 percent or better, the outlook is worse for high-risk patients, including those whose disease has spread widely. New treatments are urgently needed for these patients, less than half of whom currently enjoy long-term, disease-free survival.

"This was the first time this experimental antibody was tried in patients. We were encouraged with the response," said first and corresponding author Fariba Navid, M.D., an associate member of the St. Jude Department of Oncology. "The percentage of patients who benefited from treatment with hu14.18K322A was unusual for a Phase I study."

Phase I studies focus on questions related to the safety and best dose of experimental therapies. The research involves patient volunteers whose cancer has returned or did not respond to standard treatment, which for neuroblastoma includes surgery, chemotherapy, radiation and bone marrow transplants.

In this study, 38 St. Jude patients received one of nine different
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Experimental drug prolongs life span in mice
2. Experimental drug shows promise for treatment-resistant leukemias
3. Diabetes drug shows promise in reducing Alzheimers disease in an experimental model
4. Experimental drug could enhance multiple myeloma and myeloid leukemia therapies
5. Experimental drug shows encouraging results in treating most common form of lung cancer
6. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
7. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
8. York physicists offer novel insight into experimental cancer treatment
9. Experimental Drug Shows Benefits Against Melanoma in Early Study
10. Experimental Drugs Show Promise Against Prostate Cancer
11. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 In ... acknowledges that “bi-weekly telephonic discovery conferences would be beneficial ... such conferences through mid-December. “At the end of December,” ... assess the need for additional conferences. , “The ... recognizes that there is still much to be discussed ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... tend to outlive males, a circumstance that is usually ... especially when they compete for females. This might also ... higher parasite burden than females. Therefore, high variability of ... be more important for males. Scientists at the Research ...
... tests should not be used to predict Alzheimer,s disease, the ... Although there is a link between the two, ... their sense of smell, and it may not necessarily mean ... "A nonspecific association between poor smell function and Alzheimer,s ...
... THURSDAY, May 10 (HealthDay News) -- A new weight-loss ... and Drug Administration showed promising results in a recent ... a combination of the drugs phentermine and topiramate, experienced ... health problems, the study found. The findings were reported ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... from systemic sclerosis, also known as scleroderma, than Caucasians. ... a journal of the American College of Rheumatology (ACR), ... likely to have antibodies that increased frequency and severity ... According to the ACR there are 49,000 ...
... Chronic exposure to cocaine reduces the expression of a ... in vivo research on the molecular basis of cocaine ... which produce greater sensitivity to the rewarding effects of ... for development of a treatment for cocaine addiction. It ...
Cached Medicine News:Health News:Living longer - variability in infection-fighting genes can be a boon for male survival 2Health News:Smell Tests Don't Predict Alzheimer's, Study Finds 2Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Economic theory actually works in health care 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2Health News:Chronic cocaine use triggers changes in brain's neuron structure 2
(Date:9/17/2014)... , September 17, 2014 ... Market by Component (Sensor, Battery, Memory Device, Display, & ... Fitness & Wellness), and by Geography - Global Forecast ... medical electronics market is expected to reach $56.50 Billion ... 2014 to 2020. Browse 235 market data ...
(Date:9/17/2014)... WOONSOCKET, R.I. , Sept. 17, 2014 ... provides insights regarding patients taking Sovaldi® (sofosbuvir), a new ... The data shows that over the last several months ... and actual downward trend in Sovaldi utilization. This suggests ... number of new therapeutic regimens of similar efficacy and ...
(Date:9/17/2014)...  The law firm McElroy, Deutsch, Mulvaney & ... serve as host for "Show Me the Money: ... Healthcare Reform," a one-day conference scheduled for October ... compliance and enforcement in a marketplace re-shaped by ... -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... July 20 BIO Ventures for Global Health (BVGH) announced ... a new San Francisco headquarters office. The expansion provides BVGH the ... communities on both coasts. , , ... very excited about our expansion and new location in the Bay area, one ...
... Pathologists Outlines Recommendations at Food and Drug Administration Meeting , ... WASHINGTON , ... tests in diagnosing and treating disease, representatives of the College of ... Administration (FDA) urging increased oversight of laboratory developed tests (LDTs) and ...
Cached Medicine Technology:BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff 2BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: